CONTINUOUS AND FIXED-CYCLE DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN OF ADAPT NXT

被引：0
|
作者：
Sahagian, Gregory [1 ]
Hussain, Yessar [2 ]
Feinberg, Marc H. [3 ]
Habib, Ali A. [4 ]
Skripuletz, Thomas [5 ]
Ruck, Tobias [6 ]
Brauer, Edward [7 ]
Gelinas, Deborah [7 ]
Liu, Li [7 ]
Podhorna, Jana [7 ]
Mantegazza, Renato [8 ]
机构：
[1] Neurol Ctr Southern Calif, Carlsbad, CA USA
[2] Austin Neuromuscular Ctr, Austin, TX USA
[3] South Florida Neurol Associates, Boca Raton, FL USA
[4] Univ Calif Irvine, Dept Neurol, Irvine, CA USA
[5] Hannover Med Sch, Hannover, Germany
[6] Heinrich Heine Univ, Dept Neurol, Fac Med, Dusseldorf, Germany
[7] argenx, Ghent, Belgium
[8] Fdn IRCCS Ist Neurol Carlo Besta, Dept Neuroimmunol & Neuromuscular Dis, Milan, Italy
来源：
MUSCLE & NERVE | 2022年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S14 / S14
页数：1
相关论文
共 50 条
  • [1] CONTINUOUS AND FIXED-CYCLE DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN OF ADAPT NXT
    Gwathmey, Kelly
    Sahagian, Gregory
    Hussain, Yessar
    Feinberg, Marc
    Habib, Ali
    Skripuletz, Thomas
    Ruck, Tobias
    Rivner, Michael
    Sun, Fang
    Brauer, Edward
    Gelinas, Deborah
    Liu, Li
    Podhorna, Jana
    Mantegazza, Renato
    MUSCLE & NERVE, 2022, 66 : S110 - S110
  • [2] CYCLIC AND EVERY-OTHER-WEEK DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: PART A OF ADAPT NXT
    Habib, Ali A.
    Claeys, Kristl G.
    Bril, Vera
    Hussain, Yessar
    Gwathmey, Kelly
    Sahagian, Gregory
    Cortes-Vicente, Elena
    Brauer, Edward
    Gelinas, Deborah
    Sumbul, Anne
    Jimenez, Rosa H.
    Hristova, Daniela
    Masschaele, Delphine
    Mantegazza, Renato
    Meisel, Andreas
    Attarian, Shahram
    MUSCLE & NERVE, 2024, 70 (03) : 541 - 541
  • [3] Fixed Cycle and Q2W Dosing of Intravenous Efgartigimod for gMG: Part A of ADAPT NXT
    Bosold, Jonathan
    Brauer, Edward
    Bril, Vera
    Habib, Ali A.
    Claeys, Kristl G.
    Hussain, Yessar
    Gwathmey, Kelly
    Sahagian, Gregory
    Es-Vicente, Elena Cort
    Guptill, Jeffrey
    Gelinas, Deborah
    Sumbul, Anne
    Jimenez, Rosa H.
    Hristova, Daniela
    Masschaele, Delphine
    Mantegazza, Renato
    Meisel, Andreas
    Attarian, Shahram
    NEUROLOGY, 2024, 103 (07) : S9 - S11
  • [4] STUDY DESIGN OF INTRAVENOUS EFGARTIGIMOD IN JUVENILE GENERALIZED MYASTHENIA GRAVIS
    Kuntz, Nancy
    Schwaede, Abigail
    Bogatyreva, Anna
    Podhorna, Jana
    Steeland, Sophie
    Van Bragt, Tonke
    Van Hoorick, Benjamin
    Guglietta, Antonio
    Howard, James
    MUSCLE & NERVE, 2022, 66 : S111 - S111
  • [5] STUDY DESIGN OF INTRAVENOUS EFGARTIGIMOD IN JUVENILE GENERALIZED MYASTHENIA GRAVIS
    Kuntz, Nancy L.
    Bogatyreva, Anna
    Podhorna, Jana
    Steeland, Sophie
    Van Bragt, Tonke
    Van Hoorick, Benjamin
    Guglietta, Antonio
    Howard, James F., Jr.
    MUSCLE & NERVE, 2022, 65 : S12 - S13
  • [6] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: phase 3 adapt study results
    Mantegazza, R.
    Bril, V.
    Vu, T.
    Karam, C.
    Peric, S.
    Margania, T.
    Murai, H.
    Biliska, M.
    Shakarishvili, R.
    Smilowski, M.
    Guglietta, A.
    Ulrichts, P.
    Vangeneugden, T.
    Utsugisawa, K.
    Verschuuren, J.
    Howard, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 80 - 80
  • [7] THE EFFECT OF OBESITY IN EFFICACY AND SAFETY IN THE ADAPT TRIAL OF EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS
    Pulley, Michael
    Pasnoor, Mamatha
    Gelinas, Deborah
    Brauer, Edward
    Kerstens, Rene
    Beydoun, Said
    Howard, James
    MUSCLE & NERVE, 2022, 66 : S105 - S105
  • [8] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: Phase 3 adapt study results
    Mantegazza, Renato
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    Margania, Temur
    Murai, Hiroyuki
    Bilinska, Malgorzata
    Shakarishvili, Roman
    Smilowski, Marek
    Guglietta, Antonio
    Ulrichts, Peter
    Vangeneugden, Tony
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Howard, James
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [9] ADAPT: A PHASE 3 STUDY OF FCRN ANTAGONIST, EFGARTIGIMOD, IN MYASTHENIA GRAVIS
    Howard, James
    Tuan Vu
    Bril, Vera
    De Bleecker, Jan
    Verschuuren, Jan
    Mantegazza, Renato
    Meisel, Andreas
    Peric, Stojan
    de Haard, Hans
    Parys, Wim
    Guglietta, Antonio
    Ulrichts, Peter
    Murai, Hiroyuki
    MUSCLE & NERVE, 2020, 62 : S76 - S76
  • [10] Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study
    Howard, James
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    Murai, Hiroyuki
    Guglietta, Antonio
    Ulrichts, Peter
    Vangeneugden, Tony
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    NEUROLOGY, 2021, 96 (15)
12345